News Vector Science and Therapeutics Corp.

Stocks

PAIN

CA92244M1041

Investment Holding Companies

Market Closed - Toronto S.E. 23:59:55 06/10/2026 +04			5-day change	1st Jan Change
1.750 ^CAD	-7.89%		-6.42%	+3,400.00%

08-24	Vector Science Starts Manufacturing Pharma-Grade Peptides	MT
08-24	Vector Science & Therapeutics Increases Peptide Manufacturing Capacity At Lyogenesis Facility	CI

All News

Mentions Relevance

09-26	Vector Science and Therapeutics Corp. Issues Options	NE
08-26	Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options	AQ
08-24	Vector Science Starts Manufacturing Pharma-Grade Peptides	MT
08-24	Vector Science & Therapeutics Increases Peptide Manufacturing Capacity At Lyogenesis Facility	CI
08-24	Vector Science & Therapeutics Begins Peptide Production As First Suite At LyoGenesis Manufacturing Comes Online	CI
08-24	Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online	AQ
08-20	Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	AQ
08-20	Vector Science and Therapeutics Corp Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	CI
08-19	/C O R R E C T I O N -- Vector Sciences & Therapeutics/	AQ
08-17	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings	AQ
08-17	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement With LyoGenesis Holdings LLC	CI
07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-27	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-25	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-25	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
07-21	Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels	AQ
07-17	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist	CI
07-17	Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax	MT
07-17	Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist	AQ
07-15	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery	CI
07-15	Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies	AQ
07-08	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board	CI
07-07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus	CI
07-07	Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio	AQ
06-30	Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform	CI